



9 March 2021

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 94,882 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 6.03p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,626,991 Ordinary Shares, representing approximately 0.36 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of PDMR/person closely associated with them ("PCA")	
a)	Name	Andrew Wright
b)	Position/status	PDMR: Financial Controller and Company Secretary
c)	Initial notification/ amendment	Initial notification

2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument	Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24				
b)	Nature of the transaction	Standalone acquisition of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>GBP £0.0603</td> <td>94,882</td> </tr> </tbody> </table>	Price(s)	Volume(s)	GBP £0.0603	94,882
Price(s)	Volume(s)					
GBP £0.0603	94,882					
d)	Aggregated information - Aggregated volume - Price	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>GBP £5,721.38</td> <td>94,882</td> </tr> </tbody> </table>	Price(s)	Volume(s)	GBP £5,721.38	94,882
Price(s)	Volume(s)					
GBP £5,721.38	94,882					
e)	Date of the transaction	2021-03-08				
f)	Place of the transaction	London Stock Exchange XLON				

Enquiries:

Hemogenyx Pharmaceuticals plc

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

headquarters@hemogenyx.com

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Matthew Johnson, Vadim Alexandre, Adam Cowl

Tel: +44 (0)20 3470 0470

Peterhouse Capital Limited

Lucy Williams, Duncan Vasey, Charles Goodfellow

Tel: +44 (0)20 7469 0930